MDxHealth SA (NASDAQ:MDXH)
| Market Cap | $10.25M-96.8% |
| Revenue (ttm) | $72.63M-18.1% |
| Net Income | -$40.16M+11.0% |
| EPS | -$0.68+51.5% |
| Shares Out | 95.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,033,296 |
| Open | $0.12 |
| Previous Close | $0.12 |
| Day's Range | $0.10 - $0.12 |
| 52-Week Range | $0.10 - $4.34 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | $2.50(+2227.75%) |
| Earnings Date | n/a |
About MDXH
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating MDXH in the last 3 months, one vote each. Issuer-paid research is not counted.
$MDXH stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in MDXH holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MDXH's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MDXH Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MDXH patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MDXH from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MDXH
| IWCiShares Micro-Cap ETF | $14.95K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from MDXH’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 2026 results show revenue miss and net loss, though commercial reset narrative suggests management positioning for 2027 recovery.
